For more than two decades, hormone replacement therapy (HRT) carried one of the U.S. Food and Drug Administration’s (FDA’s) strongest safety alerts — the black box warning. This warning, prominently displayed on prescription labels, signaled serious potential risks such as heart disease, breast cancer, and dementia. But in a landmark shift announced in late 2025, the FDA initiated the removal of these warnings from many HRT products, signaling a dramatic change in how hormone therapy is viewed in menopause care.
This decision followed a comprehensive review of scientific evidence that has evolved substantially since the early 2000s, when the original warnings were added. Today, medical experts and regulatory authorities are recognizing that earlier interpretations of risk were overly broad, misunderstood, or not applicable to the majority of women who use HRT around the time of menopause. Let’s break down why the FDA removed the black box warning and what that means for women considering HRT.
A Brief History: What the Black Box Warning Said
Black box warnings, sometimes called “boxed warnings,” appear on drug labels to highlight serious or life-threatening risks that healthcare providers and patients should be aware of before using a medication. In the early 2000s, the FDA added these warnings to HRT products after results from the Women’s Health Initiative (WHI) study raised concerns. The WHI was a large government-funded clinical trial that examined long-term risks and benefits of HRT in postmenopausal women using the synthetic hormones Premarin and Prempro. The study reported increased rates of breast cancer, cardiovascular events, and stroke among women taking certain hormone therapies — leading to the FDA’s decision to include strong safety warnings on those products. As a result of that cautionary labeling:
- Use of HRT declined sharply.
- Many women avoided hormone therapy even for bothersome menopausal symptoms like hot flashes, night sweats, or vaginal dryness.
- Some clinicians became reluctant to prescribe HRT, concerned about liability or misinterpreting the risk.
What Changed? Reevaluating the Evidence
In recent years, researchers and clinicians began to question whether the black box warnings were accurately reflecting the true risk-benefit profile of HRT, especially for women who start therapy close to the onset of menopause or for those that use bio-identical forms. Several key developments informed this reevaluation:
1. Timing Matters
More recent studies have shown that the timing of HRT initiation is critical to its effects when taking synthetic hormones (Premarin/Prempro):
- Women who begin HRT within 10 years of menopause or before age 60 tend to have a more favorable risk profile than women who start therapy later in life.
- The original WHI trial enrolled many women well past this window (average age was 63), meaning the results may not generalize to typical HRT users who start earlier.
2. Modern HRT Regimens Are Different
The formulations of hormone therapy commonly used today differ greatly from those evaluated in older studies like WHI. Bio-identical or natural hormone therapies carry lower risks and offer different safety profiles. Additionally, the warnings were applied broadly to all HRT products and failed to recognize the vast difference between synthetic and Bio-identical therapies.
3. Emerging Evidence Suggests Greater Benefits
Recent analyses of multiple clinical trials and analyses of the WHI reveal that HRT may offer benefits that outweigh risks for many women when used appropriately:
- Some research has linked HRT started early in menopause to lower all-cause mortality, fewer heart attacks, reduced risk of cognitive decline, and fewer bone fractures.
Why the FDA Acted: Updating Risk Messaging
After reviewing the evolving evidence, the FDA concluded that keeping broad black box warnings on many HRT products was no longer justified and, in some cases, was discouraging appropriate use of therapy that could meaningfully improve quality of life. Here’s what the FDA’s action aimed to accomplish:
Provide Accurate, Balanced Information
The agency is working with pharmaceutical companies to update label language so it better reflects current science — including context about age, timing, and specific risks — rather than invoking fear.
Empower Patient-Provider Conversations
Health officials emphasized that decisions about HRT should be made through shared decision-making between a woman and her healthcare provider, based on her personal health history and goals, not deterred by alarmist warnings.
Improve Access to Care
By removing what some clinicians called “misleading” language, the FDA hopes to make HRT a viable option again for women suffering from significant menopausal symptoms and for women looking to optimize their health as they age. However, the FDA did not remove every warning: for example, boxed warnings remain for the risk of endometrial cancer in women using systemic estrogen alone without progesterone for women with a uterus remain in place to guide appropriate clinical use.
What This Means for Women Today
It’s critical to understand that removing the black box warning doesn’t mean HRT is risk-free. Rather, the FDA’s action reflects an effort to communicate nuanced, evidence-based information that helps women and clinicians weigh risks and benefits more accurately. (U.S. Food and Drug Administration)
Women considering HRT should still have individualized discussions with their providers that consider:
- Personal and family medical history
- Age and time since menopause
- Type of hormone therapy and delivery method
- Other health risk factors
For many women, especially those experiencing moderate to severe symptoms of menopause, removing the black box warning opens the door to more informed choices and potentially improved quality of life.
Conclusion
The FDA’s removal of the black box warning on many forms of hormone replacement therapy represents a major shift in how menopause care is communicated and understood. By incorporating modern evidence and refining risk messaging, regulators are seeking to give women and their healthcare providers a clearer, science-based framework for making decisions about hormone therapy — not one driven by outdated fears.
As research continues to evolve, this change underscores the importance of using the best available science to guide clinical practice and patient care — ensuring that women’s health decisions are rooted in evidence, context, and personalized care rather than outdated warning labels.